Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
详细信息 查看全文
- 作者：Patrick M. Moriarty ; MD<sup>asup><sup> ; sup><sup>pmoriart@kumc.edu" class="auth_mail" title="E-mail the corresponding authorsup> ; Paul D. Thompson ; MD<sup>bsup> ; Christopher P. Cannon ; MD<sup>csup> ; John R. Guyton ; MD<sup>dsup> ; Jean Bergeron ; MD<sup>esup> ; Franklin J. Zieve ; MD ; PhD<sup>fsup> ; Eric Bruckert ; MD<sup>gsup> ; Terry A. Jacobson ; MD<sup>hsup> ; Stephen L. Kopecky ; MD<sup>isup> ; Marie T. Baccara-Dinet ; MD<sup>jsup> ; Yunling Du ; PhD<sup>ksup> ; Robert Pordy ; MD<sup>lsup> ; Daniel A. Gipe ; MD<sup>lsup> ; for the ODYSSEY ALTERNATIVE Investigators<sup>1sup>
- 关键词：Lipid-lowering drugs ; Clinical trials ; PCSK9 ; Lipoproteins ; Monoclonal antibodies
- 刊名：Journal of Clinical Lipidology
- 出版年：2015
- 出版时间：November-December 2015
- 年：2015
- 卷：9
- 期：6
- 页码：758-769
- 全文大小：932 K
文摘
- ss="listitem" id="list_ulist0010">
- ss="label">•
Statin intolerance limits many patients from achieving optimal low-density lipoprotein cholesterol concentrations.
- ss="label">•
Alirocumab reduced low-density lipoprotein cholesterol levels more than ezetimibe in statin-intolerant patients.
- ss="label">•
Alirocumab led to fewer skeletal muscle adverse events compared with atorvastatin.